Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Visit V5_LAIS grass tablets by allergic rhinoconjunctivitis_EudraCT-Nr.2012-004916-79 - Visit V5 (Day 140 + - 14)

- 27/09/21 - 1 modulo, 8 itemgroups, 49 elementi, 1 linguaggio

Itemgroups: Visit, Physical examination, Medical Examination Rhinoscope, Spirometry; Peak Expiratory Flow, Medication, Hematology, Biochemistry, medication Demand

Study part: Visit V5 (Day 140 + - 14). Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Visit V6_LAIS grass tablets by allergic rhinoconjunctivitis_EudraCT-Nr.2012-004916-79 - Visit V6 (Day 196 + - 14)

- 27/09/21 - 1 modulo, 5 itemgroups, 35 elementi, 1 linguaggio

Itemgroups: Visit, Physical examination, Medical Examination Rhinoscope, Spirometry; Peak Expiratory Flow, medication Demand

Study part: Visit V6 (Day 196 + - 14). Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Visit V0 LAIS grass tablets by allergic rhinoconjunctivitis EudraCT-Nr.2012-004916-79 - Visit V0 Screening visit

- 20/09/21 - 1 modulo, 18 itemgroups, 157 elementi, 1 linguaggio

Itemgroups: Inclusion Criteria, Exclusion Criteria, demographics, Laboratory, Physical examination, Medical Examination Rhinoscope, History of allergies, Clinical symptoms, Score Rhinoconjunctivitis, Concomitant medication, medical history, skin prick test, Spirometry; Peak Expiratory Flow, Conjunctival provocation testing, diagnostics allergy, Hematology, Biochemistry, Inclusion Criteria

Study part: Visit V0 Screening visit. Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Genetic Screening For HLA-B5701 n Patients with HIV Day 1 NCT00340080 - Genetic Screening For HLA-B5701 Day 1 NCT00340080

- 20/06/17 - 1 modulo, 1 ItemGroup, 12 elementi, 1 linguaggio

ItemGroup: Day 1

NCT00340080 / VIIV-CNA106030 https://clinicaltrials.gov/ct2/show/NCT00340080 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Day 1 (Cohort Study) Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Visit 1 LAIS grass tablets by allergic rhinoconjunctivitis EudraCT-Nr.2012-004916-79 - Visit V1 (Day 0)

- 09/02/16 - 1 modulo, 6 itemgroups, 36 elementi, 1 linguaggio

Itemgroups: Visit, Physical examination, Medical Examination Rhinoscope, Spirometry; Peak Expiratory Flow, Conjunctival provocation testing, Sublingual immunotherapy

Study part: Visit V1 (Day 0). Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Visit V7_LAIS grass tablets by allergic rhinoconjunctivitis_EudraCT-Nr.2012-004916-79 - Visit V7 (Day 238 + - 14) Final examination

- 28/01/16 - 1 modulo, 5 itemgroups, 26 elementi, 1 linguaggio

Itemgroups: Visit, Physical examination, Medical Examination Rhinoscope, Spirometry; Peak Expiratory Flow, Pregnancy test

Study part: Visit V7 (Day 238 + - 14) Final examination. Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Visit V3_LAIS grass tablets by allergic rhinoconjunctivitis_EudraCT-Nr.2012-004916-79 - Visit V3 (Day 28 + - 7)

- 28/01/16 - 1 modulo, 6 itemgroups, 34 elementi, 1 linguaggio

Itemgroups: Visit, Physical examination, Medical Examination Rhinoscope, Spirometry; Peak Expiratory Flow, Medication, Conjunctival provocation testing

Study part: Visit V3 (Day 28 + - 7). Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Visit V4_LAIS grass tablets by allergic rhinoconjunctivitis_EudraCT-Nr.2012-004916-79 - Visit V4 (Day 84 + - 7)

- 28/01/16 - 1 modulo, 6 itemgroups, 34 elementi, 1 linguaggio

Itemgroups: Visit, Physical examination, Medical Examination Rhinoscope, Spirometry; Peak Expiratory Flow, Medication, Conjunctival provocation testing

Study part: Visit V4 (Day 84 + - 7). Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Visit V2_LAIS grass tablets by allergic rhinoconjunctivitis_EudraCT-Nr.2012-004916-79 - Visit V2 (Day 7+ - 2)

- 28/01/16 - 1 modulo, 4 itemgroups, 25 elementi, 1 linguaggio

Itemgroups: Visit, Physical examination, Medical Examination Rhinoscope, Spirometry; Peak Expiratory Flow

Study part: Visit V2 (Day 7+ - 2). Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Keywords

Sommario

Modelli di dati selezionati